Medicinal Chemistry Reviews

Volume 50, Chapter 4
Cardiovascular and Metabolic Diseases:  50 Years of Progress
Scott D. Edmondson, Ann E. Weber, Jason Elliott, Bruce D. Roth, and Ruth R. Wexler

1.    Introduction                                                                                                                84

2.   Hypertension and Heart Failure                                                                                84

      2.1        β-Blockers and α-Antagonists                                                                        85

      2.2       Diuretics                                                                                                           87

      2.3       Calcium Channel Blockers                                                                              87

      2.4       ACE Inhibitors                                                                                                 88

      2.5       Angiotensin II Receptor Blockers                                                                  89

      2.6       Renin Inhibitors                                                                                              89

3.   Arrhythmia                                                                                                                  90

      3.1        Class I Agents: Sodium Channel Blockers                                                     91

      3.2       Class II Agents: β-Blockers                                                                              92

      3.3       Class III Agents: Potassium Channel Blockers                                              92

      3.4       Class IV Agents: Calcium Channel Blockers                                                  93

4.   Antiplatelets and Antithrombotics                                                                           94

      4.1        Antiplatelet Agents                                                                                         94

      4.2       Anticoagulant Agents                                                                                     96

5.   Dyslipidemia                                                                                                               99

6.   Obesity                                                                                                                         102

      6.1        Anti-obesity Drugs                                                                                          103

7.   Diabetes Mellitus                                                                                                        105

      7.1        Insulin Secretagogues                                                                                     105

      7.2       Incretin-based Therapies                                                                                106

      7.3       Insulin Sensitization and Hepatic Glucose Production                                107

      7.4       Glucose Absorption/Reabsorption                                                                108

      7.5       Future Directions                                                                                             109

8.   Conclusions                                                                                                                 110

To purchase a copy, contact secretary@acsmedchem.org

ACS Division of Medicinal Chemistry

Webmaster:  secretary@acsmedchem.org